Skip to main content
. Author manuscript; available in PMC: 2019 Aug 21.
Published in final edited form as: Rheumatology (Oxford). 2017 Dec 1;56(12):2145–2153. doi: 10.1093/rheumatology/kex340

Figure 2. Kaplan-Meier One Minus Survival plots with combinations of Anti-Citrullinated Protein antibodies (ACPA) and Rheumatoid Factor (RF) and associated risks for progression to clinical arthritis over time.

Figure 2

With autoantibody-negative CSA-patients as reference (N=184), ACPA-negative/RF-positive patients (N=25) had a HR of 2.6 (1.04-6.6), ACPA-positive/RF-negative (N=6) a HR of 8.0 (2.4-27.4) and ACPA-positive/RF-positive patients (N=26) a HR of 10.5 (5.4-20.6) for progression to clinical arthritis.